SLC5A2 and atrial fibrillation: A meta-analysis of 22 clinical trials involving 52,115 patients demonstrated that treatment with SGLT2 inhibitors significantly reduced the risk of AF (relative risk [RR]: 0.82, 95% CI: 0.70–0.96) and embolic stroke (RR: 0.32, 95% CI: 0.12–0.85), irrespective of baseline glycemic status [191].